Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses

Philipp A. Kaufmann, Ornella E. Rimoldi, Tomaso Gnecchi-Ruscone, Thomas F. Luscher, Paolo G. Camici

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N G-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD). We have previously demonstrated that CFR to adenosine was significantly increased after systemic infusion of L-NMMA in normal volunteers but not in recently transplanted denervated hearts. At baseline, myocardial blood flow (MBF; ml·min -1·g -1) was measured at rest and during intravenous administration of adenosine (140 μg·kg -1·min -1) in 10 controls (47 ± 5 yr) and 10 CAD patients (58 ± 8 yr; P <0.01 vs. controls) using positron emission tomography and 15O-labeled water. Both MBF measurements were repeated during intravenous infusion of 10 mg/kg L-NMMA. CFR was calculated as the ratio of MBF during adenosine to MBF at rest. CFR was significantly higher in healthy volunteers than in CAD patients and increased significantly after L-NMMA in controls (4.00 ± 1.10 to 6.15 ± 1.35; P <0.0001) and in patients, both in territories subtended by stenotic coronary arteries (>70% luminal diameter; 2.06 ± 1.13 to 3.21 ± 1.07; P <0.01) and in remote segments (3.20 ± 1.23 to 3.92 ± 1.62; P <0.05). In conclusion, CFR can be significantly increased in CAD by a systemic infusion of L-NMMA. Similarly to our previous findings in normal volunteers, this suggests that adenosine-induced hyperemia in CAD patients is constrained by a mechanism that can be relieved by systemic NOS inhibition with L-NMMA.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume293
Issue number4
DOIs
Publication statusPublished - Oct 2007

Fingerprint

omega-N-Methylarginine
Nitric Oxide Synthase
Adenosine
Coronary Artery Disease
Pathologic Constriction
Healthy Volunteers
Hyperemia
Intravenous Administration
Arginine

Keywords

  • Autonomic nervous system
  • Cardiac imaging
  • Coronary circulation
  • Ischemic heart disease
  • Positron emission tomography

ASJC Scopus subject areas

  • Physiology

Cite this

Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses. / Kaufmann, Philipp A.; Rimoldi, Ornella E.; Gnecchi-Ruscone, Tomaso; Luscher, Thomas F.; Camici, Paolo G.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 293, No. 4, 10.2007.

Research output: Contribution to journalArticle

@article{b2f2c361fb234d05952dcf135699991e,
title = "Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses",
abstract = "We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N G-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD). We have previously demonstrated that CFR to adenosine was significantly increased after systemic infusion of L-NMMA in normal volunteers but not in recently transplanted denervated hearts. At baseline, myocardial blood flow (MBF; ml·min -1·g -1) was measured at rest and during intravenous administration of adenosine (140 μg·kg -1·min -1) in 10 controls (47 ± 5 yr) and 10 CAD patients (58 ± 8 yr; P <0.01 vs. controls) using positron emission tomography and 15O-labeled water. Both MBF measurements were repeated during intravenous infusion of 10 mg/kg L-NMMA. CFR was calculated as the ratio of MBF during adenosine to MBF at rest. CFR was significantly higher in healthy volunteers than in CAD patients and increased significantly after L-NMMA in controls (4.00 ± 1.10 to 6.15 ± 1.35; P <0.0001) and in patients, both in territories subtended by stenotic coronary arteries (>70{\%} luminal diameter; 2.06 ± 1.13 to 3.21 ± 1.07; P <0.01) and in remote segments (3.20 ± 1.23 to 3.92 ± 1.62; P <0.05). In conclusion, CFR can be significantly increased in CAD by a systemic infusion of L-NMMA. Similarly to our previous findings in normal volunteers, this suggests that adenosine-induced hyperemia in CAD patients is constrained by a mechanism that can be relieved by systemic NOS inhibition with L-NMMA.",
keywords = "Autonomic nervous system, Cardiac imaging, Coronary circulation, Ischemic heart disease, Positron emission tomography",
author = "Kaufmann, {Philipp A.} and Rimoldi, {Ornella E.} and Tomaso Gnecchi-Ruscone and Luscher, {Thomas F.} and Camici, {Paolo G.}",
year = "2007",
month = "10",
doi = "10.1152/ajpheart.01292.2006",
language = "English",
volume = "293",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses

AU - Kaufmann, Philipp A.

AU - Rimoldi, Ornella E.

AU - Gnecchi-Ruscone, Tomaso

AU - Luscher, Thomas F.

AU - Camici, Paolo G.

PY - 2007/10

Y1 - 2007/10

N2 - We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N G-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD). We have previously demonstrated that CFR to adenosine was significantly increased after systemic infusion of L-NMMA in normal volunteers but not in recently transplanted denervated hearts. At baseline, myocardial blood flow (MBF; ml·min -1·g -1) was measured at rest and during intravenous administration of adenosine (140 μg·kg -1·min -1) in 10 controls (47 ± 5 yr) and 10 CAD patients (58 ± 8 yr; P <0.01 vs. controls) using positron emission tomography and 15O-labeled water. Both MBF measurements were repeated during intravenous infusion of 10 mg/kg L-NMMA. CFR was calculated as the ratio of MBF during adenosine to MBF at rest. CFR was significantly higher in healthy volunteers than in CAD patients and increased significantly after L-NMMA in controls (4.00 ± 1.10 to 6.15 ± 1.35; P <0.0001) and in patients, both in territories subtended by stenotic coronary arteries (>70% luminal diameter; 2.06 ± 1.13 to 3.21 ± 1.07; P <0.01) and in remote segments (3.20 ± 1.23 to 3.92 ± 1.62; P <0.05). In conclusion, CFR can be significantly increased in CAD by a systemic infusion of L-NMMA. Similarly to our previous findings in normal volunteers, this suggests that adenosine-induced hyperemia in CAD patients is constrained by a mechanism that can be relieved by systemic NOS inhibition with L-NMMA.

AB - We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N G-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD). We have previously demonstrated that CFR to adenosine was significantly increased after systemic infusion of L-NMMA in normal volunteers but not in recently transplanted denervated hearts. At baseline, myocardial blood flow (MBF; ml·min -1·g -1) was measured at rest and during intravenous administration of adenosine (140 μg·kg -1·min -1) in 10 controls (47 ± 5 yr) and 10 CAD patients (58 ± 8 yr; P <0.01 vs. controls) using positron emission tomography and 15O-labeled water. Both MBF measurements were repeated during intravenous infusion of 10 mg/kg L-NMMA. CFR was calculated as the ratio of MBF during adenosine to MBF at rest. CFR was significantly higher in healthy volunteers than in CAD patients and increased significantly after L-NMMA in controls (4.00 ± 1.10 to 6.15 ± 1.35; P <0.0001) and in patients, both in territories subtended by stenotic coronary arteries (>70% luminal diameter; 2.06 ± 1.13 to 3.21 ± 1.07; P <0.01) and in remote segments (3.20 ± 1.23 to 3.92 ± 1.62; P <0.05). In conclusion, CFR can be significantly increased in CAD by a systemic infusion of L-NMMA. Similarly to our previous findings in normal volunteers, this suggests that adenosine-induced hyperemia in CAD patients is constrained by a mechanism that can be relieved by systemic NOS inhibition with L-NMMA.

KW - Autonomic nervous system

KW - Cardiac imaging

KW - Coronary circulation

KW - Ischemic heart disease

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=35349031658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349031658&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.01292.2006

DO - 10.1152/ajpheart.01292.2006

M3 - Article

C2 - 17660388

AN - SCOPUS:35349031658

VL - 293

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 4

ER -